Drugs 2022 Jun 27. Epub 2022 Jun 27.
Department of Medicine, University of California Irvine School of Medicine, 101 The City Drive South, Building 200, Room 410, ZOT 4061, Orange, CA, 92868, USA.
Background And Objective: Trastuzumab deruxtecan (T-DXd) is a novel anti-ERBB2 antibody drug conjugate that appears to be associated with an increased risk of lung toxicity. We performed a systematic review to describe the incidence, severity, and management of T-DXd-induced interstitial lung disease (ILD) or pneumonitis.
Methods: We searched PubMed/MEDLINE, Embase, Cochrane, and Web of Sciences through to 1 January, 2022, for human clinical trials that assessed T-DXd in adults with ERBB2-positive advanced solid tumors and described the rate of ILD/pneumonitis. Read More